Phospholipase A2, Secretory, Group IIA, Recombinant, Human (PLA2, sPLA2-IIA)

Phospholipase A2 (PLA2) catalyzes the hydrolysis of the sn-2 position of membrane glycerophospholipids to liberate arachidonic acid (AA), a precursor of eicosanoids including prostaglandins and leukotrienes. The same reaction also produces lysophosholipids, which represent another class of lipid mediators. The secretory PLA2 (sPLA2) family, in which 10 isozymes have been identified, consists of lowmolecular weight, Ca2+-requiring secretory enzymes that have been implicated in a number of biological processes, such as modification of eicosanoid generation, inflammation, and host defense. This enzyme has been proposed to hydrolyze phosphatidylcholine (PC) in lipoproteins to liberate lyso- PC and free fatty acids in the arterial wall, thereby facilitating the accumulation of bioactive lipids and modified lipoproteins in atherosclerotic foci. In mice, sPLA2 expression significantly influences HDL particle size and composition and demonstrate that an induction of sPLA2 is required for the decrease in plasma HDL cholesterol in response to inflammatory stimuli. Instillation of bacteria into the bronchi was associated with surfactant degradation and a decrease in large:small ratio of surfactant aggregates in rats. sPLA2-IIA can exert beneficial action in the context of infectious diseases since recent studies have shown that this enzyme exhibits potent bactericidal effects. Induction of the synthesis of sPLA2-IIA is generally initiated by endotoxin and a limited number of cytokines via paracrine and/or autocrine processes.\n\nDescription: \nThe Recombinant Human Secreted Phospholipase A2-IIA is manufactured with N-terminal fusion of HisTag. The Recombinant Human Secreted Phospholipase A2-IIA His-Tagged Fusion Protein is 15.8kD containing 124aa residues of the human secreted phospholipase A2-IIA and 16 additional amino acid residues

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

P4074-06E2

Size

2ug

Form

Supplied as a lyophilized powder from 0.05M acetate buffer, pH 4.0. Add 200ul of 0.1M Acetate buffer pH4 and let the lyophilized pellet dissolve completely. For conversion into higher pH value, we recommend intensive dilution by relevant buffer to a concentration of 10 ug/ml. In higher concentrations the solubility of this antigen is limited.

Purity

(same/more than) 95% (SDS-PAGE); Purified by a three-step procedure using affinity Ni-NTA chromatography and size exclusion chromatography before and after refolding.

References

1. Arterioscler. Thromb. Vasc. Biol. 26(7): 1421-1422 (2006). 2. Cardiovasc. Hematol. Disord. Drug Targets 6(2): 113-123 (2006). 3. J. Invest. Dermatol. 126(4): 855-861 (2006). 4. J. Lipid Res. 46(8): 1604-1614 (2005). 5. J. Lipid Res. 46(2): 201-210 (2005).